Side-by-side · Research reference

IpamorelinvsVilon

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 1HUMAN-REVIEWED21/57 cited

BAnimal-StrongHUMAN-REVIEWED13/49 cited

Ipamorelin

Selective GHRP · Ghrelin Mimetic

200–300 mcgPer doseRaun 1998

Phase 1Evidence levelRaun 1998 Sigalos 2018

~2 hrHalf-lifeRaun 1998

SQ · Multiple sites · 1–3×/day

Vilon

Khavinson Bioregulator · Dipeptide

2 AADipeptide

T-helperStimulatesLinkova 2011

MouseModel basisKhavinson 2002

Literature lacks standardised clinical route

01Mechanism of Action

Parameter

Ipamorelin

Vilon

Primary target

Ghrelin receptor (GHS-R1a) on anterior pituitaryRaun 1998

Immune cell differentiation pathways, chromatin modification

Pathway

GHS-R1a binding → Gαq/11 → ↑intracellular Ca²⁺ → GH vesicle exocytosisRaun 1998 Bowers 1991

Vilon → Thymocyte sphingomyelinase activation → T-helper & cytotoxic T-cell differentiation; epigenetic suppression of aging markers (CCL11, HMGB1)

Downstream effect

GH pulse amplification, IGF-1 elevation, recovery and lipolytic effectsBowers 2002

Enhanced T-cell differentiation (CD4+, CD8+, B-cells), thymocyte proliferation, modulated IL-1β comitogenic activity, proposed chromatin decondensation in aged lymphocytesLinkova 2011 Khavinson 2002 Lezhava 2023

Feedback intact?

Yes — pulsatile pattern preserved; somatostatin feedback activeBowers 2002

Unknown — no HPA/HPG axis data

Origin

Pentapeptide H-Aib-His-D-2-Nal-D-Phe-Lys-NH₂; rationally designed for ghrelin-receptor selectivityRaun 1998

Synthetic dipeptide derived from Khavinson thymic peptide extraction studies (Thymalin fraction)Morozov 1997

Antibody development

Not reported in short-term studies

—

02Dosage Protocols

Parameter

Ipamorelin

Vilon

Standard dose

200–300 mcg per injectionRaun 1998

Anecdotal community range; clinical doses 1–3 mg IV in trials.

No clinical standard — literature lacks human dosing

Russian practice: often combined with other Khavinson peptides; no FDA/EMA trials.

Frequency

1–3× per day

Once daily pre-sleep is most common; twice or thrice for advanced users.

Unknown — literature does not specify chronic administration protocols

Lower / starter dose

100 mcg per dose

—

Evidence basis

Phase 1 + clinical practiceRaun 1998 Sigalos 2018

Mouse / in vitro only

Duration

8–12 weeks on / 4 weeks off (anecdotal)

GHS-R desensitisation reported with continuous dosing.

Not characterised in humans

Reconstitution

Bacteriostatic water; typical 2 mL per 5 mg vial

—

Timing

Pre-sleep + fasted preferred; 30 min away from food

—

Half-life

~2 hoursRaun 1998

Longer than GHRP-6 (15 min); shorter than CJC-1295-DAC (~8 days).

Not published — dipeptides typically <10 min plasma t½

Animal model dose

—

In vitro: 0.01–10 μg/mL culture medium (mouse thymocytes)

Not translatable to human mg/kg without pharmacokinetic data.

Route

—

Likely SQ or oral (Khavinson school uses both); no published ROA validation

04Side Effects & Safety

Parameter

Ipamorelin

Vilon

Cortisol elevation

Negligible vs other GHRPsRaun 1998

—

Prolactin elevation

NegligibleRaun 1998

—

Hunger

Mild appetite increase via ghrelin-receptor crosstalk

—

Injection site reaction

Mild irritation possible

—

GH excess (overdose)

Joint pain, edema, insulin resistance

—

IGF-1 elevation

Dose-dependent; monitor with chronic high-dose use

—

Cancer risk

Theoretical via GH/IGF-1 axis; contraindicated in active malignancy

—

Pregnancy / OB

Avoid

—

Human safety data

—

Absent from PubMed-indexed literature

Theoretical risk

—

Immune hyperactivation in autoimmune-prone individuals (T-cell differentiation enhancement)

Antibody formation

—

Not reported; dipeptides generally low immunogenicity

Animal models

—

No adverse effects noted in mouse thymocyte or pineal lymphoid cultures

Absolute Contraindications

Ipamorelin

·Active malignancy or cancer history
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

Vilon

·Active autoimmune disease (theoretical — no clinical data)

Relative Contraindications

Ipamorelin

·Untreated diabetes
·Severe insulin resistance
·Concurrent corticosteroid use (theoretical desensitisation)

Vilon

·Pregnancy / lactation (no safety data)
·Acute infection with cytokine storm risk (immune modulation unknown)

05Administration Protocol

Parameter

Ipamorelin

Vilon

1. Reconstitution

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL. Roll gently. Solution should be clear.

No clinical protocols exist in Western peer-reviewed literature. Russian gerontological practice may use 1–10 mg ranges, but dosing is empirical.

2. Injection site

Subcutaneous, abdomen or thigh. Rotate sites. Pinch fat for shallow SQ delivery.

Subcutaneous injection (common for Khavinson peptides) or oral (some bioregulators reportedly active orally due to small size). No validated ROA.

3. Timing

Pre-sleep optimal — aligns with natural GH pulse. Some protocols add a morning fasted dose.

Unknown — no circadian or meal-timing data. Khavinson school often recommends morning administration.

4. Storage

Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.

Likely lyophilised powder, refrigerated. Reconstitution protocols not published.

5. Needle

29–31G, 4–8 mm insulin syringe.

—

06Stack Synergy

Ipamorelin

+ Tesamorelin

Strong

View Tesamorelin →

Ipamorelin (GHRP) + tesamorelin (GHRH analogue) is the textbook dual-axis GH stack. They activate two distinct pituitary receptors — the ghrelin receptor and the GHRH receptor — producing a synergistic GH pulse larger than either alone. Ipamorelin's selectivity (no cortisol/prolactin spike) makes it the ideal GHRP partner for long-term protocols.

Ipamorelin: 200–300 mcg SQ · pre-sleep
Tesamorelin: 2 mg SQ · same injection · pre-sleep
Primary benefit: Maximal GH pulsatility, fat loss, recovery, sleep depth

Raun 1998 Bowers 2002

+ CJC-1295 (no DAC)

Strong

View CJC-1295 (no DAC) →

CJC-1295 (no DAC) is a short-acting GHRH analogue. Combined with ipamorelin (GHRP), the pulse is amplified across both receptor systems with timing similar to native physiology. Without the DAC modification, the stack maintains sharp peaks rather than the sustained elevation seen with CJC-1295-DAC + ipamorelin.

Ipamorelin: 200–300 mcg SQ · pre-sleep
CJC-1295 (no DAC): 100 mcg SQ · same injection
Primary benefit: Pulsatile GH stimulation matching physiological pattern

Teichman 2006 Ionescu 2006

Vilon

+ Epitalon

Moderate

View Epitalon →

Both are Khavinson bioregulators targeting aging pathways. Epitalon (Ala-Glu-Asp-Gly) acts on telomerase and pineal function; Vilon on immune differentiation and chromatin decondensation. Combined in Russian gerontological protocols for multi-system aging intervention. Lezhava et al. (2023) tested both on aged lymphocyte chromatin, showing distinct epigenetic effects. Complementary, not synergistic in strict pharmacological sense.

Vilon: Empirical — no standard
Epitalon: Empirical — often 10 mg cycles
Frequency: Sequential or concurrent (literature ambiguous)
Primary benefit: Multi-system aging modulation (immune + pineal/circadian)

+ Thymalin

Weak

View Thymalin →

Thymalin is the parent polypeptide complex from which Vilon was isolated. Both target immune differentiation, but Thymalin is a complex mixture (multiple peptides), whereas Vilon is a purified dipeptide. Morozov & Khavinson (1997) described Vilon as a synthetic successor designed to replicate Thymalin's immunomodulatory effects with greater specificity. Redundant in practice; no published combination studies.

Vilon: No standard
Thymalin: 10–100 mg IM (polypeptide complex)
Primary benefit: Redundant — both target T-cell differentiation

Morozov 1997 Khavinson 2020